PNM 300 Test 3 Prep Document | 2026/2027 Edition | 200
Verified Questions - 200 Questions with Answers
PNM 300 Test 3 2026-200 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously crafted for nursing students preparing
for PNM 300 Test 3. It features 200 verified practice questions that mirror the actual exam's format and
content, ensuring thorough readiness. Each question is accompanied by detailed rationales that explain
the correct answer and why the distractors are incorrect, promoting deep understanding. The content is
aligned with the latest 2026/2027 curriculum guidelines, guaranteeing relevance and accuracy. With a
pass guarantee and A+ grading, this resource is an essential tool for achieving exam success.
Key Features:
Foundations of Professional Nursing: Historical perspectives, nursing theories, and professional roles.
Legal and Ethical Issues in Nursing: Legal liabilities, ethical principles, and patient rights.
Health Assessment and Physical Examination: Techniques for comprehensive patient assessment.
Pharmacology and Medication Administration: Drug classifications, calculations, and safe administration.
Pathophysiology and Disease Management: Understanding disease processes and interventions.
Nursing Process and Critical Thinking: ADPIE, clinical reasoning, and care planning.
Patient Education and Health Promotion: Teaching strategies and preventive care.
Communication and Interpersonal Skills: Therapeutic communication and documentation.
Evidence-Based Practice and Research: Appraising and applying research findings.
Leadership and Management in Nursing: Delegation, prioritization, and team coordination.
Quality Improvement and Patient Safety: QSEN competencies and error prevention.
Cultural Competence and Diversity: Culturally sensitive care and health disparities.
Maternal and Child Health Nursing: Prenatal, intrapartum, postpartum, and pediatric care.
Medical-Surgical Nursing: Adult health conditions and perioperative care.
Mental Health Nursing: Psychiatric disorders and therapeutic interventions.
Community and Public Health Nursing: Population health and epidemiology.
Updates for 2026:
- Revised to reflect the latest NCLEX-RN test plan and PNM 300 course objectives.
- Incorporated updated clinical practice guidelines and evidence-based protocols.
- Enhanced rationales with current research and best practices.
- Added new questions on emerging healthcare trends and technologies.
- Aligned content with 2026/2027 academic year curriculum changes.
Abstract:
This exam preparation document for PNM 300 Test 3 is a comprehensive resource designed to facilitate mastery of
essential nursing concepts. It encompasses a wide range of topics, from foundational theories to advanced clinical
skills, ensuring a holistic review. The 200 practice questions are crafted to challenge the student's critical thinking
and application abilities, with detailed rationales that reinforce learning. The content is rigorously updated to
align with the 2026/2027 curriculum and current healthcare standards. By engaging with this material, students
will enhance their knowledge, confidence, and test-taking strategies, ultimately leading to a successful outcome on
the exam. The document serves as an indispensable tool for nursing students committed to excellence in their
professional education.
Page 1
,Keywords:
PNM 300, Test 3 Prep, Nursing Exam, Practice Questions, Rationales, 2026/2027, NCLEX, A+ Graded
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale. The
rationale explains the underlying concept, the reason the correct answer is right, and why the other options are
incorrect. This format promotes active learning and helps students understand the 'why' behind each answer.
Compliance Checklist:
Aligned with the latest PNM 300 course syllabus and objectives.
Updated to reflect 2026/2027 academic year guidelines.
Includes 200 verified practice questions with detailed rationales.
Covers all major content areas and domains of the course.
Designed to meet the rigor of actual exam conditions.
Pass guarantee ensures student satisfaction.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Nursing 1-25 History, Theories, Professional Roles 12.5%
Legal and Ethical Issues 26-45 Legal Liabilities, Ethics, Patient Rights 10%
Health Assessment 46-70 Physical Exam, Vital Signs, Documentation 12.5%
Pharmacology 71-95 Drug Classifications, Calculations, 12.5%
Administration
Pathophysiology and Disease 96-120 Disease Processes, Interventions, 12.5%
Management Complications
Nursing Process and Critical 121-140 ADPIE, Clinical Reasoning, Care Planning 10%
Thinking
Patient Education and Health 141-155 Teaching Strategies, Preventive Care, Health 7.5%
Promotion Literacy
Communication and 156-170 Therapeutic Communication, 7.5%
Interpersonal Skills Documentation, Interprofessional
Communication
Evidence-Based Practice and 171-180 Research Methods, Appraisal, 5%
Research Implementation
Leadership and Management 181-190 Delegation, Prioritization, Team 5%
Coordination
Quality Improvement and 191-195 QSEN, Error Prevention, Safety Protocols 2.5%
Patient Safety
Cultural Competence and 196-200 Culturally Sensitive Care, Health 2.5%
Diversity Disparities, Communication
Page 2
,Q1. A patient on long-term warfarin therapy is started on a new medication that
inhibits CYP2C9. Which change in warfarin pharmacodynamics is most expected?
A. Increased warfarin clearance due to enzyme induction
B. Reduced anticoagulant effect due to receptor antagonism
C. Enhanced anticoagulant effect due to decreased warfarin metabolism
D. No change in warfarin effect because CYP2C9 inhibition is clinically irrelevant
Correct Answer: C. Enhanced anticoagulant effect due to decreased warfarin
metabolism
Rationale: CYP2C9 is the primary enzyme metabolizing the S-enantiomer of warfarin.
Inhibition of CYP2C9 decreases warfarin metabolism, leading to elevated plasma levels
and enhanced anticoagulant effect. Enzyme induction (A) would increase clearance,
reducing effect; receptor antagonism (B) is not a relevant mechanism for warfarin;
CYP2C9 inhibition is clinically significant (D).
Why Wrong:
A - Enzyme induction would increase warfarin metabolism, decreasing its effect, not
enhancing it.
B - Warfarin acts by inhibiting vitamin K epoxide reductase, not by receptor
antagonism.
D - CYP2C9 inhibition significantly increases warfarin levels and bleeding risk, so it
is clinically relevant.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
(Anticoagulants)
Q2. In a patient with chronic heart failure, which drug combination demonstrates a
synergistic neurohormonal blockade that reduces mortality more than either agent
alone?
A. Digoxin and furosemide
B. ACE inhibitor and beta-blocker
C. Hydralazine and isosorbide dinitrate
D. Spironolactone and loop diuretic
Correct Answer: B. ACE inhibitor and beta-blocker
Rationale: ACE inhibitors and beta-blockers target complementary neurohormonal
pathways (RAAS and sympathetic nervous system). Their combined use has shown additive
mortality benefit in heart failure with reduced ejection fraction. Digoxin and furosemide
(A) treat symptoms but do not provide synergistic mortality reduction;
hydralazine/isosorbide (C) is a second-line option, not synergistic with ACE inhibitors;
spironolactone and loop diuretics (D) manage fluid and aldosterone but do not provide the
same synergistic mortality benefit.
Why Wrong:
A - Digoxin and furosemide improve symptoms but lack mortality benefit and do not
Page 3
, synergistically block neurohormonal systems.
C - Hydralazine/isosorbide is beneficial in specific populations (e.g., African
Americans) but not synergistic with ACE inhibitors.
D - Spironolactone and loop diuretics are used for fluid management and aldosterone
blockade, but not for synergistic mortality reduction.
Reference: Yancy, C.W., et al. (2022). ACC/AHA/HFSA Heart Failure Guideline.
Circulation.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is
prescribed metformin. Which adjustment is required per current guidelines?
A. No adjustment needed; metformin is safe at any eGFR
B. Discontinue metformin because it is nephrotoxic
C. Reduce the dose and monitor renal function more frequently
D. Switch to sulfonylurea because it is safer in CKD
Correct Answer: C. Reduce the dose and monitor renal function more frequently
Rationale: Metformin is contraindicated at eGFR <30 mL/min, but at eGFR 30-45
mL/min, it may be continued at a reduced dose with close monitoring of renal function. It
is not nephrotoxic (B), but accumulation can cause lactic acidosis. Sulfonylureas (D) carry
hypoglycemia risk and are not inherently safer.
Why Wrong:
A - Metformin requires dose adjustment and monitoring for eGFR between 30 and 45
mL/min.
B - Metformin is not nephrotoxic, but its clearance is renal, so accumulation can
occur.
D - Sulfonylureas have their own risks and are not preferred over metformin in CKD.
Reference: American Diabetes Association. (2026). Standards of Care in Diabetes-2026.
Diabetes Care.
Q4. Which pharmacodynamic principle best explains why a drug with a high
therapeutic index is safer than one with a low therapeutic index?
A. It has a wider margin between the minimum effective concentration and the toxic
concentration
B. It has a shorter half-life, allowing rapid elimination if toxicity occurs
C. It is less likely to bind to plasma proteins, increasing free drug concentration
D. It produces a maximal effect at a lower dose
Correct Answer: A. It has a wider margin between the minimum effective
concentration and the toxic concentration
Rationale: Therapeutic index (TI) is the ratio of the median toxic dose to the median
effective dose. A high TI means a wide margin between effective and toxic concentrations,
Page 4
Verified Questions - 200 Questions with Answers
PNM 300 Test 3 2026-200 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously crafted for nursing students preparing
for PNM 300 Test 3. It features 200 verified practice questions that mirror the actual exam's format and
content, ensuring thorough readiness. Each question is accompanied by detailed rationales that explain
the correct answer and why the distractors are incorrect, promoting deep understanding. The content is
aligned with the latest 2026/2027 curriculum guidelines, guaranteeing relevance and accuracy. With a
pass guarantee and A+ grading, this resource is an essential tool for achieving exam success.
Key Features:
Foundations of Professional Nursing: Historical perspectives, nursing theories, and professional roles.
Legal and Ethical Issues in Nursing: Legal liabilities, ethical principles, and patient rights.
Health Assessment and Physical Examination: Techniques for comprehensive patient assessment.
Pharmacology and Medication Administration: Drug classifications, calculations, and safe administration.
Pathophysiology and Disease Management: Understanding disease processes and interventions.
Nursing Process and Critical Thinking: ADPIE, clinical reasoning, and care planning.
Patient Education and Health Promotion: Teaching strategies and preventive care.
Communication and Interpersonal Skills: Therapeutic communication and documentation.
Evidence-Based Practice and Research: Appraising and applying research findings.
Leadership and Management in Nursing: Delegation, prioritization, and team coordination.
Quality Improvement and Patient Safety: QSEN competencies and error prevention.
Cultural Competence and Diversity: Culturally sensitive care and health disparities.
Maternal and Child Health Nursing: Prenatal, intrapartum, postpartum, and pediatric care.
Medical-Surgical Nursing: Adult health conditions and perioperative care.
Mental Health Nursing: Psychiatric disorders and therapeutic interventions.
Community and Public Health Nursing: Population health and epidemiology.
Updates for 2026:
- Revised to reflect the latest NCLEX-RN test plan and PNM 300 course objectives.
- Incorporated updated clinical practice guidelines and evidence-based protocols.
- Enhanced rationales with current research and best practices.
- Added new questions on emerging healthcare trends and technologies.
- Aligned content with 2026/2027 academic year curriculum changes.
Abstract:
This exam preparation document for PNM 300 Test 3 is a comprehensive resource designed to facilitate mastery of
essential nursing concepts. It encompasses a wide range of topics, from foundational theories to advanced clinical
skills, ensuring a holistic review. The 200 practice questions are crafted to challenge the student's critical thinking
and application abilities, with detailed rationales that reinforce learning. The content is rigorously updated to
align with the 2026/2027 curriculum and current healthcare standards. By engaging with this material, students
will enhance their knowledge, confidence, and test-taking strategies, ultimately leading to a successful outcome on
the exam. The document serves as an indispensable tool for nursing students committed to excellence in their
professional education.
Page 1
,Keywords:
PNM 300, Test 3 Prep, Nursing Exam, Practice Questions, Rationales, 2026/2027, NCLEX, A+ Graded
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale. The
rationale explains the underlying concept, the reason the correct answer is right, and why the other options are
incorrect. This format promotes active learning and helps students understand the 'why' behind each answer.
Compliance Checklist:
Aligned with the latest PNM 300 course syllabus and objectives.
Updated to reflect 2026/2027 academic year guidelines.
Includes 200 verified practice questions with detailed rationales.
Covers all major content areas and domains of the course.
Designed to meet the rigor of actual exam conditions.
Pass guarantee ensures student satisfaction.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Nursing 1-25 History, Theories, Professional Roles 12.5%
Legal and Ethical Issues 26-45 Legal Liabilities, Ethics, Patient Rights 10%
Health Assessment 46-70 Physical Exam, Vital Signs, Documentation 12.5%
Pharmacology 71-95 Drug Classifications, Calculations, 12.5%
Administration
Pathophysiology and Disease 96-120 Disease Processes, Interventions, 12.5%
Management Complications
Nursing Process and Critical 121-140 ADPIE, Clinical Reasoning, Care Planning 10%
Thinking
Patient Education and Health 141-155 Teaching Strategies, Preventive Care, Health 7.5%
Promotion Literacy
Communication and 156-170 Therapeutic Communication, 7.5%
Interpersonal Skills Documentation, Interprofessional
Communication
Evidence-Based Practice and 171-180 Research Methods, Appraisal, 5%
Research Implementation
Leadership and Management 181-190 Delegation, Prioritization, Team 5%
Coordination
Quality Improvement and 191-195 QSEN, Error Prevention, Safety Protocols 2.5%
Patient Safety
Cultural Competence and 196-200 Culturally Sensitive Care, Health 2.5%
Diversity Disparities, Communication
Page 2
,Q1. A patient on long-term warfarin therapy is started on a new medication that
inhibits CYP2C9. Which change in warfarin pharmacodynamics is most expected?
A. Increased warfarin clearance due to enzyme induction
B. Reduced anticoagulant effect due to receptor antagonism
C. Enhanced anticoagulant effect due to decreased warfarin metabolism
D. No change in warfarin effect because CYP2C9 inhibition is clinically irrelevant
Correct Answer: C. Enhanced anticoagulant effect due to decreased warfarin
metabolism
Rationale: CYP2C9 is the primary enzyme metabolizing the S-enantiomer of warfarin.
Inhibition of CYP2C9 decreases warfarin metabolism, leading to elevated plasma levels
and enhanced anticoagulant effect. Enzyme induction (A) would increase clearance,
reducing effect; receptor antagonism (B) is not a relevant mechanism for warfarin;
CYP2C9 inhibition is clinically significant (D).
Why Wrong:
A - Enzyme induction would increase warfarin metabolism, decreasing its effect, not
enhancing it.
B - Warfarin acts by inhibiting vitamin K epoxide reductase, not by receptor
antagonism.
D - CYP2C9 inhibition significantly increases warfarin levels and bleeding risk, so it
is clinically relevant.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
(Anticoagulants)
Q2. In a patient with chronic heart failure, which drug combination demonstrates a
synergistic neurohormonal blockade that reduces mortality more than either agent
alone?
A. Digoxin and furosemide
B. ACE inhibitor and beta-blocker
C. Hydralazine and isosorbide dinitrate
D. Spironolactone and loop diuretic
Correct Answer: B. ACE inhibitor and beta-blocker
Rationale: ACE inhibitors and beta-blockers target complementary neurohormonal
pathways (RAAS and sympathetic nervous system). Their combined use has shown additive
mortality benefit in heart failure with reduced ejection fraction. Digoxin and furosemide
(A) treat symptoms but do not provide synergistic mortality reduction;
hydralazine/isosorbide (C) is a second-line option, not synergistic with ACE inhibitors;
spironolactone and loop diuretics (D) manage fluid and aldosterone but do not provide the
same synergistic mortality benefit.
Why Wrong:
A - Digoxin and furosemide improve symptoms but lack mortality benefit and do not
Page 3
, synergistically block neurohormonal systems.
C - Hydralazine/isosorbide is beneficial in specific populations (e.g., African
Americans) but not synergistic with ACE inhibitors.
D - Spironolactone and loop diuretics are used for fluid management and aldosterone
blockade, but not for synergistic mortality reduction.
Reference: Yancy, C.W., et al. (2022). ACC/AHA/HFSA Heart Failure Guideline.
Circulation.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is
prescribed metformin. Which adjustment is required per current guidelines?
A. No adjustment needed; metformin is safe at any eGFR
B. Discontinue metformin because it is nephrotoxic
C. Reduce the dose and monitor renal function more frequently
D. Switch to sulfonylurea because it is safer in CKD
Correct Answer: C. Reduce the dose and monitor renal function more frequently
Rationale: Metformin is contraindicated at eGFR <30 mL/min, but at eGFR 30-45
mL/min, it may be continued at a reduced dose with close monitoring of renal function. It
is not nephrotoxic (B), but accumulation can cause lactic acidosis. Sulfonylureas (D) carry
hypoglycemia risk and are not inherently safer.
Why Wrong:
A - Metformin requires dose adjustment and monitoring for eGFR between 30 and 45
mL/min.
B - Metformin is not nephrotoxic, but its clearance is renal, so accumulation can
occur.
D - Sulfonylureas have their own risks and are not preferred over metformin in CKD.
Reference: American Diabetes Association. (2026). Standards of Care in Diabetes-2026.
Diabetes Care.
Q4. Which pharmacodynamic principle best explains why a drug with a high
therapeutic index is safer than one with a low therapeutic index?
A. It has a wider margin between the minimum effective concentration and the toxic
concentration
B. It has a shorter half-life, allowing rapid elimination if toxicity occurs
C. It is less likely to bind to plasma proteins, increasing free drug concentration
D. It produces a maximal effect at a lower dose
Correct Answer: A. It has a wider margin between the minimum effective
concentration and the toxic concentration
Rationale: Therapeutic index (TI) is the ratio of the median toxic dose to the median
effective dose. A high TI means a wide margin between effective and toxic concentrations,
Page 4
